Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Miracll Chemicals Co.,Ltd (300848.SZ)
Yantai, CN
Miracll Chemicals Co., Ltd. is an enterprise focused on the research, development, production, and sale of advanced thermoplastic polyurethane (TPU) elastomers and specialized polyol products. Their extensive product line includes a variety of TPUs derived from different chemical bases, such as polyester, polyether, thermoplastic olefin polyurethane, and polycaprolactone. Additionally, the company provides functional TPUs, including expandable, expanded, and adhesive-grade variants for both hot-melt and solvent-based applications. These versatile materials are utilized in a wide array of sectors, spanning electronics, sports and recreation, automotive, medical devices, renewable energy, household goods, 3D printing, and general industrial uses. Miracll Chemicals Co., Ltd. was established in 2009 and operates from its headquarters in Yantai, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Chemicals - Specialty: +4.7%+5.3% ★ Q1'26: +47.7% (vs Q1'25)
-
EPS growth Chemicals - Specialty: +13.2%+0.0% Q1'26: +50.0% (vs Q1'25)
-
FCF margin FCF growth · Chemicals - Specialty: +44.1%+12.1% Q1'26: -58.4% (vs Q1'25)
-
EBIT margin Chemicals - Specialty: +8.8%+5.4% Q1'26: +6.6% (vs Q1'25)
-
ROIC Chemicals - Specialty: +5.6%+4.5% Q1'26: +5.4% (vs Q1'25)
-
Share dilution Chemicals - Specialty: +0.1%+5.6% Q1'26: 0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Chemicals - Specialty: 0.18×6.40× Q1'26: 8.65× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
1.30B
est: 1.44B (-9.6%)
|
1.48B
est: 1.61B (-8.5%)
|
1.48B
est: 1.61B (-8.5%)
|
1.66B
est: 2.06B (-19.4%)
|
1.75B
est: 2.03B (-13.8%)
|
2.64B
2.64B – 2.64B
+30.4% YoY
|
3.66B
3.66B – 3.66B
+38.6% YoY
|
| EBITDA |
157.31M
est: 160.00M (-1.7%)
|
143.78M
est: 179.73M (-20.0%)
|
128.84M
est: 179.73M (-28.3%)
|
121.61M
est: 195.73M (-37.9%)
|
168.36M
est: 192.78M (-12.7%)
|
251.39M
251.39M – 251.39M
+30.4% YoY
|
348.45M
348.45M – 348.45M
+38.6% YoY
|
| EBIT |
134.84M
est: 130.50M (+3.3%)
|
117.98M
est: 146.59M (-19.5%)
|
100.50M
est: 146.59M (-31.4%)
|
81.81M
est: 146.01M (-44.0%)
|
93.57M
est: 143.81M (-34.9%)
|
187.54M
187.54M – 187.54M
+30.4% YoY
|
259.94M
259.94M – 259.94M
+38.6% YoY
|
| Net Income |
119.15M
est: 101.57M (+17.3%)
|
111.28M
est: 100.52M (+10.7%)
|
87.86M
est: 100.52M (-12.6%)
|
77.59M
est: 90.55M (-14.3%)
|
81.93M
est: 202.66M (-59.6%)
|
349.27M
349.27M – 349.27M
+72.3% YoY
|
607.99M
607.99M – 607.99M
+74.1% YoY
|
| SGA |
38.36M
est: 25.37M (+51.2%)
|
44.18M
est: 28.50M (+55.0%)
|
53.79M
est: 28.50M (+88.7%)
|
62.16M
est: 61.29M (+1.4%)
|
27.10M
est: 60.36M (-55.1%)
|
78.72M
78.72M – 78.72M
+30.4% YoY
|
109.11M
109.11M – 109.11M
+38.6% YoY
|
| EPS |
0.31
est: 0.25 (+24.6%)
|
0.28
est: 0.25 (+13.8%)
|
0.22
est: 0.25 (-10.6%)
|
0.19
est: 0.21 (-9.5%)
|
0.19
est: 0.47 (-59.6%)
|
0.81
0.81 – 0.81
+72.3% YoY
|
1.41
1.41 – 1.41
+74.1% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 60.6K | 0.29% |
| 2 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 91.9K | 0.07% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 17.3K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Guanglei Ren | Marketing Director & Non-Independent Director | — | male |
| Sheng Zhang | GM & Director | — | male |
| Ying Tao Du | CFO & Board Secretary | — | male |
| Yue Wang | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300848.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
